Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

(2020) Gilles Salles et al.   LANCET ONCOLOGY

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

(2020) Nagesh Kalakonda et al.   Lancet Haematology

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

(2020) Bicky Thapa et al.   Blood Advances

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

(2020) Mehdi Hamadani et al.   BLOOD

CAR-T Cell Therapy in B cell Non-Hodgkin Lymphomas

(2019) Adam Levin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Rapid Relapse of Large B‐Cell Lymphoma after CD19 Directed CAR‐T‐Cell Therapy due to CD‐19 Antigen Loss

(2019) Ali Bukhari et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical lessons learned from the first leg of the CAR T cell journey

(2019) Robbie G. Majzner et al.   NATURE MEDICINE

Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy

(2019) Veronika Bachanova et al.   BLOOD REVIEWS

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

(2019) Brad S. Kahl et al.   CLINICAL CANCER RESEARCH

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2019) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

(2019) Xinjie Xu et al.   Frontiers in Immunology

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

(2018) Francesca Zammarchi et al.   BLOOD

How I manage patients with relapsed/refractory diffuse large B cell lymphoma

(2018) Christian Gisselbrecht et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

(2018) Elena J. Orlando et al.   NATURE MEDICINE

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

(2018) John A. Hartley et al.   Scientific Reports

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

2016 US lymphoid malignancy statistics by World Health Organization subtypes

(2016) Lauren R. Teras et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011

(2015) Mohammed Al-Hamadani et al.   AMERICAN JOURNAL OF HEMATOLOGY

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY